{"@id":"https://pharmgkb.org/literature/15075342","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15075342,"resourceId":"21712851","title":"Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A.","authors":["Budhiraja Pooja","Popovtzer Mordecai"],"journal":"Nature reviews. Nephrology","month":6,"page":"478-84","pubDate":"2011-06-01T00:00:00-07:00","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21712851","summary":"BACKGROUND: A 50-year-old man who had received a simultaneous pancreas and kidney transplant 9 years earlier developed pancytopenia 3 weeks after starting azathioprine therapy to treat worsening proteinuria suspected to be caused by sirolimus.\n\nMETHODS: Laboratory tests, including complete blood counts, measurement of serum levels of vitamin B(12) and folate, liver function tests, virological assays, and thiopurine S-methyltransferase (TPMT) genotyping.\n\nMETHODS: Severe myelosuppression as a consequence of azathioprine therapy in a patient homozygous for the TPMT*3A allele.\n\nRESULTS: Discontinuation of azathioprine, treatment with an erythropoiesis-stimulating agent, red blood cell transfusions, filgrastim (a granulocyte colony-stimulating factor analogue) and folic acid.","type":"article","volume":"7","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21712851","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449280863,"resource":"PubMed","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21712851","xrefId":"21712851"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/nrneph.2011.74","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449280864,"resource":"Digital Object Identifiers","sameAs":"http://dx.doi.org/10.1038%2Fnrneph.2011.74","xrefId":"10.1038/nrneph.2011.74"}],"year":2011}